Treatment masking Sample Clauses

Treatment masking. The contact lens group in this study is double-masked, with contact lens group subjects randomized to use AOHG MF, DT1 MF or DACP MF lenses for the study visit. Investigators will be masked to the type and brand of PAL. Unmasked Study Coordinator(s) The Unmasked Study Coordinator(s) will manage IP inventory, as well as IP administration. This individual will have access to IP supply, accountability logs, and other documents or supplies pertaining to IP (including brand/type of PAL). The unmasked coordinator will also assist with device deficiency and adverse event reporting. The Unmasked Study Coordinator(s) will be unmasked to allow for storage and dispensing, as well as accountability for all contact lens IP. Clinical Operations Lead (COL) The COL will have access to IP supply, accountability logs, and other documents or supplies pertaining to IP. This individual assists with masked and unmasked data reviews. The COL will be unmasked to allow for oversight of the CSM, in conjunction with all IP accountability tasks. Clinical Site Manager (CSM) CSM will have access to IP supply, accountability logs, and other documents or supplies pertaining to IP accountability. This individual monitors unmasked and masked study data. The CSM will be unmasked to allow for performance of IP accountability, management of device deficiencies and related AE lens returns, and any other IP related tasks. Unmasked Data Manager(s) The Unmasked Data Manager(s) will have access to restricted fields in eDC that would contain unmasking data. The Unmasked Data Manager(s) will be unmasked to allow for review of all restricted data. IRT Manager The IRT manager will be unmasked to allow for system programming, The IRT manager is unmasked to all aspects of Unmasked Individual Extent of Unmasking Rationale testing, and to allow for technical oversight of the system. the trial for system development purposes. Randomization Specialist The Randomization specialist will be unmasked to allow for generation of the randomization list and uploading of that list into the IRT system. Generates and therefore has full knowledge of treatment codes but otherwise is operationally not associated with the Clinical Trial Team or any decision-making aspects related to clinical trial design, execution, or reporting. This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked. Masked study per...
Sample 1
AutoNDA by SimpleDocs
Treatment masking. This study is subject-masked, with subjects randomized to use the TOTAL30 contact lenses and AOHP contact lenses for the duration of the 28 and 14 day treatment period, respectively. This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked.
Sample 1
Treatment masking. This study is double-masked, with subjects randomized in a 1:1 ratio to receive Toric and Biofinity Toric contact lenses in a crossover sequence for the duration of the two 30-day treatment period. Unmasking will occur only after all planned study data have been validated, and the database locked. Masked study personnel must avoid seeking information that may compromise masking. In the event of a medical emergency where the knowledge of subject treatment is required, an individual investigator will have the ability to unmask the treatment assignment for a specific subject after contacting an appropriate study sponsor representative if time allows.
Sample 1
Treatment masking. This study is double-masked, with subjects randomized to use lenses for the duration of the 3-month treatment period. or Biofinity contact
Sample 1
Treatment masking. This study is double-masked, with subjects randomized to use lenses for the duration of the 12-month treatment period. or Biofinity contact contacted prior to unmasking. Unmasking must be done according to the instructions provided for the study IRT system.
Sample 1
Treatment masking. This study is double-masked. All members associated with the study (at the site and the study sponsor) are masked to the assigned treatment This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked. Masked study personnel must avoid seeking information that may compromise masking. In the event of a medical emergency where the knowledge of subject treatment is required, an individual investigator will have the ability to unmask the treatment assignment for a specific subject after contacting an appropriate study sponsor representative if time allows.
Sample 1
Treatment masking. This study is double-masked, with subjects randomized to use or Biofinity contact lenses for the duration of the 3-month treatment period. All members associated with the study (at the site and the Study Sponsor) will be masked to the assigned treatment This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked. Masked study personnel must avoid seeking information that may compromise masking. In the event of a medical emergency where the knowledge of subject treatment is required, individual Investigator(s) will have the ability to unmask the treatment assignment for a specific subject. If time allows, the appropriate Study Sponsor representative should be contacted prior to unmasking. Unmasking must be done according to the instructions provided for the study IRT system.
Sample 1
AutoNDA by SimpleDocs
Treatment masking. This study is double-masked, with subjects randomized to use DACP Digital and DACP lenses (in a crossover fashion) for the duration of the 7 ± 2 day treatment period for each lens product. This level of masking will be maintained throughout the conduct of the study. Unmasking will occur only after all planned study data have been validated, and the database locked.‌ Masked study personnel must avoid seeking information that may compromise masking. Unmasked study personnel must not disseminate information that is potentially unmasking to any masked personnel. The masked and unmasked site personnel must coordinate all study activities as necessary to protect masking and minimize bias during the study. In the event of a medical emergency where the knowledge of subject treatment is required, an individual Investigator will have the ability to unmask the treatment assignment for a specific subject after contacting an appropriate Study Sponsor representative if time allows. Unmasking must be done according to the instructions provided for the study IRT system.
Sample 1

Related to Treatment masking

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State. (2) In addition, each Contracting Party shall accord to investors of the other Contracting Party, including in respect of returns on their investments, treatment which shall not be less favourable than that accorded to investors of any third State. (3) The provisions of paragraphs (1) and (2) above shall not be construed so as to oblige one Contracting Party to extend to the investors of the other the benefit of any treatment, preference or privilege resulting from: (a) Any existing or future free trade area, customs unions, monetary union or similar international agreement or other forms of regional cooperation to which one of the Contracting Parties is or may become a party, or (b) Any matter pertaining wholly or mainly to taxation.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Defendants, and Defendants shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Defendants or any of their subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • Treatment of Fees The fees described in this Section 5 (a) are not compensation for the use, detention, or forbearance of money, (b) are in addition to, and not in lieu of, interest and expenses otherwise described in this Agreement, (c) are payable in accordance with Section 3.1(c), (d) are non-refundable, and (e) to the fullest extent permitted by Law, bear interest, if not paid when due, at the Default Rate.

  • Reorganization Treatment Neither the Company nor any Company Subsidiary has taken or agreed to take any action that would prevent the Merger from constituting a reorganization qualifying under the provisions of Section 368(a) of the Code.

  • Recycling If this Agreement provides for the purchase or use of goods specified in PCC 12207 (for example, certain paper products, office supplies, mulch, glass products, lubricating oils, plastic products, paint, antifreeze, tires and tire-derived products, and metal products), this section is applicable with respect to those goods. Without limiting the foregoing, if this Agreement includes (i) document printing, (ii) parts cleaning, or (iii) janitorial and building maintenance services, this section is applicable. Contractor shall use recycled products in the performance of this Agreement to the maximum extent doing so is economically feasible. Upon request, Contractor shall certify in writing under penalty of perjury, the minimum, if not exact, percentage of post consumer material as defined in the PCC 12200, in such goods regardless of whether the goods meet the requirements of PCC 12209. With respect to printer or duplication cartridges that comply with the requirements of PCC 12156(e), the certification required by this subdivision shall specify that the cartridges so comply.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!